MOZOM-analyse
MOZOM compares: WHO warning about counterfeit DARZALEX, chain leak or warning signal?
- Source
- WHO
- MOZOM headline
- MOZOM compares: WHO warning about counterfeit DARZALEX, chain leak or warning signal?
- Original headline
- WHO warns of counterfeit DARZALEX injections found in Mexico and Maldives
- Author
- Ron Caroselli
- Date
- 3 juli 2026 om 19:43
- Subject
- The World Health Organization warns about two counterfeit batches of DARZALEX, a drug containing daratumumab that is used for multiple myeloma and AL amyloidosis, among other things.
Summary of the original report
The World Health Organization issued Medical Product Alert No. on July 3, 2026. Published 3/2026 on counterfeit DARZALEX injections. According to the WHO, this concerns two batches found in Mexico and the Maldives and reported by national regulators in May and June 2026. The products were supplied or offered by unauthorized distributors; in at least one case, hospitals received the counterfeit products. According to WHO, the real manufacturer has confirmed that the batch numbers MYS7381 and STV1K01 are invalid. The WHO says products with these batch numbers should not be used and calls on healthcare professionals and regulators to report suspicious products, quality defects and unexpected effects.
Own source research
MOZOM has compared the two WHO source layers. Layer One: The concrete alert names Mexico, the Maldives, two batch numbers, unauthorized distributors, and at least one hospital that received counterfeit products. Layer two: the WHO fact sheet describes why counterfeit medical products are often difficult to recognize and how complex chains, informal markets and online sales make detection more difficult. Layer three is the MOZOM interpretation: with a drug for rare blood diseases and bone marrow cancer, the damage is not only visible as direct poisoning. Missed or ineffective treatment can also be serious. Therefore, the key question is not only who supplied the boxes, but how quickly hospitals, pharmacies, manufacturers, regulators and cross-border networks can find each other.
Striking in this message
It is striking that the word forged can sound too small here. With luxury products, counterfeiting is often about brand and money. With an injectable medicine, this concerns content, sterility, dosage and the question of whether a patient receives real treatment in time. The WHO also points out that visible particles have been found in at least one adulterated batch, making the warning more concrete than just an administrative batch issue.
Less visible context
Less visible is the dependence on specialist healthcare chains. A patient usually does not see where exactly a medicine was purchased, through which distributor it came and what checks were carried out along the way. Especially with expensive specialist products, the temptation for counterfeiters can be great, while the burden of control falls on healthcare institutions and supervisors. The social question is therefore who in the chain has enough insight to stop a counterfeit product before it is administered to a vulnerable patient.
Possible message behind the news
A possible message is that patient safety not only starts with the doctor and the protocol, but also with the less visible route of manufacturer, distributor, regulator, pharmacy and hospital stock.
Neutral conclusion
The neutral conclusion: WHO warns about specific counterfeit DARZALEX batches and recommends increased vigilance, reporting and use of authorized suppliers. The more pointed MOZOM reading is that this is not just a product alert, but a test of confidence for the specialist medicine chain. This is analysis, not medical advice; Anyone who suspects a suspicious product or possible side effect should follow the WHO guidance and immediately contact a competent healthcare professional or supervisor.